Examkin

Question

Difficulty: HardEnd-of-Life and Palliative Care

Match each advanced end-of-life clinical scenario to the most appropriate next step in targeted pharmacological management.

  • An 82-year-old with end-stage renal disease (glomerular filtration rate of 8 mL/min) receiving hospice care who develops severe myoclonus and diffuse hyperalgesia while on high-dose oral morphine.Perform opioid rotation to subcutaneous fentanyl or methadone
  • A 68-year-old actively dying of metastatic lung cancer who develops distressing 'death rattle' oropharyngeal secretions alongside severe agitated delirium.Administer glycopyrrolate rather than scopolamine
  • A 74-year-old with advanced ovarian cancer presenting with an inoperable malignant bowel obstruction, intractable nausea, and severe colicky abdominal pain.Initiate continuous subcutaneous octreotide and dexamethasone
  • A 59-year-old with terminal pancreatic cancer experiencing refractory terminal delirium that has not responded to escalating doses of haloperidol and chlorpromazine.Initiate palliative sedation with continuous intravenous midazolam

Answer

Morphine-induced neurotoxicity in renal failure maps to opioid rotation (fentanyl/methadone); terminal secretions with co-occurring delirium maps to glycopyrrolate (avoids CNS penetration); malignant bowel obstruction maps to octreotide and dexamethasone; and refractory terminal delirium maps to palliative sedation with midazolam.
Each correct pairing matches a complex, refractory end-of-life symptom presentation with its highly specific targeted pharmacological intervention based on pharmacokinetics (renal vs. hepatic clearance), blood-brain barrier permeability, or neuroendocrine mechanisms (somatostatin analog effects on the gut).

Step-by-Step Solution

1
Analyze the physiology of the renal failure patient on morphine.
Identify accumulation of the neurotoxic metabolite M3G.
This accumulation explains the new-onset myoclonus and hyperalgesia, necessitating a switch to hepatically cleared opioids.
2
Assess the pharmacological properties required for the dying patient with secretions and delirium.
Select glycopyrrolate over scopolamine.
Glycopyrrolate is a quaternary amine that does not cross the blood-brain barrier, thereby drying secretions without worsening the existing delirium.
3
Determine the optimal medical management for an inoperable malignant bowel obstruction.
Identify the combination of octreotide and dexamethasone.
This combination minimizes gastrointestinal secretions and reduces bowel wall edema, alleviating the colicky pain and distension.
4
Evaluate the management options for terminal delirium unresponsive to neuroleptics.
Select palliative sedation.
When standard antipsychotics fail in an actively dying patient, proportional sedation with midazolam is ethically and medically required to relieve distress.

Key Concept

Advanced pharmacological symptom management in end-of-life care
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic